Biopharmaceutical News and Research

RSS

SAFC Pharma augments assay development capabilities

SAFC Pharma, a business segment of SAFC, a member of the Sigma-Aldrich group, today announced that it has commenced operations at its 7,000 sq. ft. state-of-the-art laboratory complex in Carlsbad, CA.

29 Jan 2009

First artemisinin based malaria drug may meet resistance, expert says

This year, the U.S. Food and Drug Administration is expected to approve the first malaria drug to contain artemisinin, a wormwood derivative from China that has proven effective for malaria in Africa and Asia.

8 Jan 2009

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

8 Jan 2009

Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program

Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.

6 Jan 2009

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.

8 Dec 2008

SemBioSys begins phase I/II trial of insulin produced in plant seeds

SemBioSys Genetics Inc., a biotechnology company developing protein pharmaceuticals in crop plants, has announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans.

3 Dec 2008

Antineoplaston treatment for gliomas granted orphan drug designation by FDA

The Burzynski Research Institute, Inc. (BRI) has announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases.

2 Dec 2008

Ceregene announces data from phase 2 clinical trial of CERE-120 for Parkinson's

Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.

26 Nov 2008

FDA accepts Vanda Pharmaceuticals Iloperidone resubmission

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda's resubmission of the iloperidone New Drug Application (NDA).

20 Nov 2008

MaxCyte STX scalable transfection system launched in London

MaxCyte, Inc announced today the European launch of the MaxCyte STX Scalable Transfection System at SMi's Cell-Based Assay Conference held in London, November 19 and 20, 2008.

18 Nov 2008

Innocoll receives fast track designation for Gentamicin surgical implant

Innocoll, Inc., a privately-held biopharmaceutical company, announced that the FDA has designated Gentamicin surgical implant as a Fast Track development program.

17 Nov 2008

NicOx's Naproxcinod shows highly significant reduction in daytime blood pressure versus Naproxen

NicOx S.A. has announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA.

12 Nov 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Domainex has core intellectual property rights granted for Europe

Domainex Ltd (Domainex), an innovative biopharmaceutical company, today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

From Domainex 14 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

New technique measures formation of clumps of proteins in protein-based pharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals.

23 Jul 2008

Bioscience fund GBS invests US$6m in Xenome

Biopharmaceutical company Xenome Limited today announced it has received a convertible note placement of US$6 million from GBS Venture Partners, a Melbourne based life sciences specialist that invests in unlisted and listed high growth companies involved in innovative technologies.

23 Jul 2008

Roche starts acquisition process of ARIUS - fast tracks access to screening platform for antibody therapeutics

Roche and ARIUS Research Inc. have announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

23 Jul 2008